What is the 13F Pro Quality Score for CDNA?

13F Pro ranks CareDx, Inc. (CDNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CDNA's current score at https://13fpro.ai/company/CDNA (free sign-up required for the full ranking).

Which hedge funds own the most CDNA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CDNA include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CDNA as soon as new 13F filings post.

Where does 13F Pro source CDNA data?

All CareDx, Inc. fundamentals and ownership data come directly from SEC EDGAR. CareDx, Inc. files with the SEC under CIK 1217234. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CDNA in?

CareDx, Inc. (CDNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives CDNA's revenue?

Per CareDx, Inc.'s latest 10-Q filed with the SEC on 2026-07-30, the biggest revenue drivers are: Testing services revenue ($99.9M, +61% YoY); Patient and digital solutions revenue ($19.2M, +50% YoY); Product revenue ($12.8M, +8% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/CDNA.

What are CDNA's largest expenses?

CareDx, Inc.'s latest 10-Q reports these as the largest expense items: General and administrative ($40.9M, +48% YoY); Sales and marketing ($33.4M, +38% YoY); Research and development ($22.4M, +33% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is CDNA research updated on 13F Pro?

CDNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CareDx, Inc.(CDNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1217234 CDNA stock profile & AI dashboard →

13F Pro Quality Score

67.5/100

Rank #361 of 2,960 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

83.1/100

Profitability

87.9/100

Balance Sheet

97.1/100

Earnings Quality

59.7/100

Free Cash Flow

71.2/100

Institutional Flow

40.2/100

Revenue Scale

35.8/100

Dilution Risk

17.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CDNA Scores 68/100

exact factor attribution · 2026-09-11

CDNA's composite is driven by revenue growth and profitability, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.6 pts

83th pct

Profitability

+5.7 pts

88th pct

Capital efficiency

+4.7 pts

97th pct

Free cash flow

+3.2 pts

71th pct

Earnings quality

+1.0 pts

60th pct

Earnings growth

+0.6 pts

63th pct

Institutional flow

-0.5 pts

40th pct

Shareholder dilution

-1.6 pts

17th pct

Scale

-2.1 pts

36th pct

Latest change (2026-08-03): 45 → 44 · ↓ Free cash flow 51→36

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CDNA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CareDx, Inc. (CDNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CDNA at 67.5/100 on a 32-signal composite quality model, placing it at rank #361 of 2,960 stocks — the top 25% of the AI-ranked universe. CDNA scores in the top quartile across balance sheet strength (97.1), profitability (87.9), revenue growth (83.1). Areas of concern include revenue scale (35.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CareDx, Inc. reports quarterly revenue of $131.9M, net income of $110.6M, free cash flow of $28.7M. Top institutional holders of CDNA by reported 13-F value include BlackRock, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CDNA trades on the Nasdaq exchange and files with the SEC under CIK 1217234. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CDNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CareDx, Inc. directly from SEC EDGAR. CareDx, Inc.'s 13F Pro composite quality score has ranged between 24 and 68 since 2021, currently 67.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about CareDx, Inc.

Quirks, history, and lore behind CDNA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare technology company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, built almost entirely on testing and surveillance services for a very specific patient population.
3
The History
Founded in the late 1990s, the company spent years quietly cornering a niche before going public on Nasdaq under a ticker that hints at DNA.
4
The Secret
Its core business is monitoring whether a patient's body is rejecting a transplanted organ — using cell-free DNA tests to catch rejection before symptoms even appear.
5
The Lore
Its flagship test, AlloSure, analyzes donor DNA circulating in a recipient's bloodstream — essentially letting a transplanted heart or kidney send an SOS signal through a blood draw.
6
The Giveaway
If you've ever had a transplant and your doctor ordered a liquid biopsy to check for rejection, there's a good chance this company — whose ticker literally spells CDNA — ran that test.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving CDNA's Business? Latest 10-Q Breakdown

✓ 37/37 datapoints verified

AI-extracted from CareDx, Inc.'s 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue grew 52% YoY to $131.9M and CareDx swung to $110.6M net income, driven largely by a $113.0M one-time gain on the June 30 sale of its lab products business rather than core operating leverage.

Biggest Revenue Drivers

Testing services revenue$99.9M+61% YoY

Driven by 17% testing volume growth and $18.0M of increased net collections for tests performed in prior periods, partly offset by a $2.4M increase in the refunds reserve to payers

Patient and digital solutions revenue$19.2M+50% YoY

Higher pharmacy sales and growth in digital solutions, particularly an expanded customer base from Ottr software

Biggest Revenue Drivers

Total revenue: $131.9M+52% YoY

Testing services revenue$99.9M+61% YoY

Driven by 17% testing volume growth and $18.0M of increased net collections for tests performed in prior periods, partly offset by a $2.4M increase in the refunds reserve to payers

Patient and digital solutions revenue$19.2M+50% YoY

Higher pharmacy sales and growth in digital solutions, particularly an expanded customer base from Ottr software

Product revenue$12.8M+8% YoY

Higher sales of commercial NGS-based kitted solutions

Largest Expense Items

General and administrative$40.9M+48% YoY

Increases of $5.6M personnel-related costs, $5.6M legal and consulting expenses, and $2.3M stock-based compensation

Sales and marketing$33.4M+38% YoY

Increases of $8.7M personnel-related costs and $1.0M marketing expenses, partly offset by lower stock-based compensation

Research and development$22.4M+33% YoY

Increases of $4.0M personnel-related costs, $0.8M consulting and licensing expense, and $0.5M partnership milestone expense

Cost of patient and digital solutions$14.7M+78% YoY

Increase in cost of goods from the pharmacy business

Margins: Operating income swung to $113.2M from an $11.1M operating loss a year earlier, almost entirely due to the $113.0M gain on sale of the lab products business; underlying opex (R&D, S&M, G&A) all grew faster than revenue.

Watch Items from the Filing

Medicare represented approximately 30% of total revenue and 37% of testing services revenue in Q2 2026 (down from 34% and roughly 41% a year earlier), leaving CareDx exposed to reimbursement policy changes.
Net income of $110.6M was driven almost entirely by a $113.0M non-recurring gain on the June 30, 2026 sale of the lab products business to Eurobio for ~$171.7M; underlying operations remained near breakeven.
Testing services revenue included $18.0M (of $99.9M) from net collections on tests performed in prior periods, a favorable but not necessarily recurring contributor to reported quarterly growth.
It is reasonably possible CareDx could face a loss of up to $96.3 million plus interest in the Natera patent litigation if Natera prevails on its pending appeal, though the Company currently views the loss as not probable.
Subsequent to quarter-end, CareDx completed the $161.8M cash acquisition of Naveris (plus up to $100.0M in revenue-based earnouts through FY2027), expanding into specialty oncology testing, a market where the Company has limited operating experience.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$131.9M

Net Income

Q2 2026

$110.6M

Free Cash Flow

Q2 2026

$28.7M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+13.8% YoY

$379.8MFY 2025

FY22 $321.8MFY23 $280.3MFY24 $333.8MFY25 $379.8M

Net Income

-140.6% YoY

$-21.4MFY 2025

FY22 $-76.6MFY23 $-190.3MFY24 $52.5MFY25 $-21.4M

Operating Income

-175.5% YoY

$-30.8MFY 2025

FY22 $-77.2MFY23 $-203.4MFY24 $40.8MFY25 $-30.8M

EPS (Diluted)

-143.0% YoY

$-0.40FY 2025

FY22 $-1.44FY23 $-3.54FY24 $0.93FY25 $-0.40

Total Assets

-15.8% YoY

$413.2MFY 2025

FY22 $543.0MFY23 $466.8MFY24 $491.1MFY25 $413.2M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+10.5% YoY

$42.0MFY 2025

FY22 $-25.2MFY23 $-18.4MFY24 $38.0MFY25 $42.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$379.8M +13.8%	$333.8M +19.1%	$280.3M -12.9%	$321.8M +8.6%	$296.4M +54.2%	$192.2M
Net Income	$-21.4M -140.6%	$52.5M +127.6%	$-190.3M -148.4%	$-76.6M -149.9%	$-30.7M -63.8%	$-18.7M
Operating Income	$-30.8M -175.5%	$40.8M +120.0%	$-203.4M -163.3%	$-77.2M -159.8%	$-29.7M -32.0%	$-22.5M
EPS (Diluted)	$-0.40 -143.0%	$0.93 +126.3%	$-3.54 -145.8%	$-1.44 -144.1%	$-0.59 -47.5%	$-0.40
Total Assets	$413.2M -15.8%	$491.1M +5.2%	$466.8M -14.0%	$543.0M -4.2%	$566.6M +53.8%	$368.5M
Total Debt	—	—	—	—	—	$0.00
Operating Cash Flow	$42.0M +10.5%	$38.0M +306.9%	$-18.4M +27.1%	$-25.2M -30.8%	$-19.3M -157.7%	$33.4M

Get alerted when CDNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CareDx, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CDNA

BlackRock, Inc.
$137.2M4,814,709 sh
STATE STREET CORP
$70.4M2,468,858 sh
VANGUARD CAPITAL MANAGEMENT LLC
$62.6M2,197,475 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$56.9M1,997,618 sh
ARK Investment Management LLC
$55.7M1,953,531 sh
Boston Partners
$55.2M1,937,601 sh
BAMCO INC /NY/
$55.2M1,937,326 sh
GAGNON SECURITIES LLC
$50.5M1,770,735 sh
Chevy Chase Trust Holdings, LLC
$41.0M1,437,416 sh
GEODE CAPITAL MANAGEMENT, LLC
$37.9M1,328,037 sh

Fund	Value	Shares
BlackRock, Inc.	$137.2M	4,814,709
STATE STREET CORP	$70.4M	2,468,858
VANGUARD CAPITAL MANAGEMENT LLC	$62.6M	2,197,475
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$56.9M	1,997,618
ARK Investment Management LLC	$55.7M	1,953,531
Boston Partners	$55.2M	1,937,601
BAMCO INC /NY/	$55.2M	1,937,326
GAGNON SECURITIES LLC	$50.5M	1,770,735
Chevy Chase Trust Holdings, LLC	$41.0M	1,437,416
GEODE CAPITAL MANAGEMENT, LLC	$37.9M	1,328,037

Companies Similar to CDNA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 16 shared holders

ARK Investment Management LLC BAMCO INC /NY/Nikko Asset Management Americas, Inc.

INSP

Inspire Medical Systems, Inc.

AI score

Similar quality profile · 8 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)BRAIDWELL LP abrdn plc

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 8 shared holders

BRAIDWELL LP FRED ALGER MANAGEMENT, LLC JACOBS LEVY EQUITY MANAGEMENT, INC

KNSA

Kiniksa Pharmaceuticals International, plc

AI score

Similar quality profile · 8 shared holders

BRAIDWELL LP ArrowMark Colorado Holdings LLC SILVERCREST ASSET MANAGEMENT GROUP LLC

LGND

LIGAND PHARMACEUTICALS INC

AI score

Similar quality profile · 8 shared holders

abrdn plc Uniplan Investment Counsel, Inc.JACOBS LEVY EQUITY MANAGEMENT, INC

TMDX

TransMedics Group, Inc.

AI score

Similar quality profile · 6 shared holders

BRAIDWELL LP Portolan Capital Management, LLC ArrowMark Colorado Holdings LLC

CPRX

CATALYST PHARMACEUTICALS, INC.

AI score

Similar quality profile · 4 shared holders

Boston Partners ROYCE & ASSOCIATES LP CenterBook Partners LP

VCEL

Vericel Corp

AI score

Similar quality profile · 10 shared holders

SILVERCREST ASSET MANAGEMENT GROUP LLC abrdn plc Divisadero Street Capital Management, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CDNA on your watchlist

Track score changes the day CareDx, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CDNA a good stock to buy?

13F Pro's AI-powered analysis of CareDx, Inc. (CDNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CDNA are available on the CDNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CDNA is classified as a mid company.

Which hedge funds own CDNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CDNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CareDx, Inc.'s investment landscape.